We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




C-Peptide Responsiveness May Explain HbA1c Variation

By LabMedica International staff writers
Posted on 24 Apr 2019
The addition of timing measures of C-peptide responsiveness may partly explain the glycated hemoglobin (HbA1c) level variation at diagnosis of type 1 diabetes (T1D) during the oral glucose tolerance test (OGTT).

Previous studies have reported C-peptide responsiveness changes during the progression to T1D, but there are no data regarding the timing of C-peptide responses at diagnosis and the association with glucose levels. More...
The goal of a new trial was to study whether timing of C-peptide responsiveness during test OGTT might explain variance in HbA1c levels at diagnosis of T1D.

Scientists at the Indiana University School of Medicine (Indianapolis, IN, USA) and their colleagues enrolled 85 patients age <18 years at diagnosis (mean age, 11.2 years; 51% boys) with complete OGTT data and HbA1c measurement at diagnosis. Peak C-peptide, area under the curve C-peptide, and measures of relative timing were recorded, including early C-peptide response, late C-peptide response, the 120-minute/30-minute C-peptide ratio, and time to peak C-peptide.

The team reported that there was an inverse correlation between HbA1c with measures of overall C-peptide responsiveness: area under the curve C-peptide and peak C-peptide. The inverse correlation was consistent with both early and late C-peptide responses and the 120-minute/30-minute C-peptide ratio. In 27 patients with a peak C-peptide at ≤60 minutes, HbA1c levels were higher compared with 58 participants with a peak C-peptide at >60 minutes. Similar to HbA1c, there was also inverse correlation between 2-hour glucose levels after OGTT with early and late C-peptide responses.

The authors concluded that their findings show that the addition of timing measures of C‐peptide responsiveness better explains HbA1c variation at diagnosis than standard measures alone. The study was published on March 20, 2019, in the journal Pediatric Diabetes.

Related Links:
Indiana University School of Medicine


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Portable Electronic Pipette
Mini 96
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.